MA vs PFE: Which Is the Better Buy?
Side-by-side comparison of Mastercard Incorporated and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Mastercard Incorporated · Financial Services
$574.42
+25.0% upside to fair value
Med Conviction
Grade A-
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
MA has more upside to fair value
(+25.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MA |
PFE |
| Current Price |
$574.42 |
$27.64 |
| Fair Value Estimate |
$718.00 |
$30.94 |
| Upside to Fair Value |
+25.0%
|
+12.0%
|
| Market Cap |
$503.8B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
23.4x
|
17.4x
|
| Price / Sales |
14.4x
|
2.5x
|
| Price / FCF |
30.8x
|
14.3x
|
| Revenue Growth YoY |
+14.1%
|
+2.6%
|
| Gross Margin |
100%
|
71.3%
|
| Operating Margin |
59.8%
|
25.1%
|
| Return on Equity |
232.5%
|
4.9%
|
| Dividend Yield |
0.59% |
6.22% |
| FCF Yield |
3.25%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Mastercard operates a global payments network that connects issuers, acquirers, merchants and consumers across more than 200 countries and territories, monetizing payment volumes, cross-border activity and higher-growth value-added services. Business quality is high because its two-sided network, trusted authorization-clearing-settlement infrastructure, brand, security capabilities and broad acce…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
MA |
PFE |
| Zone Low |
$538.50 |
$23.21 |
| Zone High |
$610.30 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|